You searched for "AMD"
Assessing everyday visual function in dry AMD – what matters to the person?
Age-related macular degeneration (AMD) is the primary cause of blindness in the developed world and is accountable for more than one half of sight impairment registrations within England and Wales [1]. AMD is prevalent in people aged 60 years and...Neovascular AMD: fresh recommendations underline standards of best practice
The management of neovascular age-related macular degeneration (nAMD) has advanced dramatically over the past seven years, with the introduction of targeted new therapies that successfully maintain or improve vision in a majority of affected individuals. It’s a fast moving field,...
How does cataract surgery affect eyes with wet AMD?
In this retrospective cohort study the authors’ primary objective was to assess whether cataract surgery in eyes with wet age-related macular degeneration (AMD), triggered its progression. The surgical group comprised of 40 eyes versus 42 eyes in the non-surgical control...
OCT prognostic factors in AMD patients with peripapillary choroidal neovascularisation
In this retrospective study the authors aimed to investigate the correlation between optical coherence tomography (OCT) findings and visual acuity outcomes after treatment with intravitreal bevacizumab (IVB) injections for age-related macular degeneration (AMD) patients with peripapillary choroidal neovascularisation (PPCNV). Data...Strategies for managing neovascular AMD and DMO in routine clinical care
Treatment practice in the management of neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DMO) illustrate increasing adoption of patient-tailored treatment approaches based on initial diagnosis and regular monitoring of imaging and visual outcomes in routine clinical care. The...Do patient demographics influence AMD clinic attendance during COVID-19 lockdown?
The authors assess the impact of the COVID-19 pandemic on adherence to scheduled clinic appointments among age-related macular degeneration patients in a clinic in North Wales. The COVID-19 pandemic has significantly affected the population, affecting economic and social wellbeing, whilst...The role of injection assistant devices in establishing a nurse-led AMD service
The author shares his experience of setting up a nurse-led service to deliver anti-VEGF intravitreal injections and how injection assistant devices supported training. Age-related macular degeneration (AMD) has become a leading cause of irreversible blindness [1]. It is estimated that...
Injection frequency and anatomic outcomes following conversion to Aflibercept in neovascular AMD patients
This is a retrospective study of patients with neovascular age-related macular degeneration (AMD) treated with intravitreal Lucentis and / or Avastin who were switched to aflibercept (Eylea). This study was carried out by the Casey Eye Institute retinal clinics, between...
Progression of macular atrophy on long-term anti-VEGF therapy for AMD
This retrospective study evaluated the progression of macular atrophy in 53 eyes of 53 patients receiving AntiVEGF Therapy for age-related macular degeneration (nAMD), for at least six years. None of the patients had any macular atrophy (MA) at presentation. MA...Revolutionize AMD Treatment with PBM Therapy
Integrate the eye-light® device into your practice for non-invasive, scientifically validated Photobiomodulation (PBM) therapy. Targeting AREDS 3 and lower, it slows dry AMD progression using Light Modulation LLLT. Red (630nm) boosts ATP, restores mitochondria, and reduces inflammation, while Yellow (590nm)...
